Merck to consolidate media accounts

Share this article:

Merck will consolidate media duties on all of its brands, including the newly acquired Schering-Plough portfolio, after a review.

The move, first reported by Adweek, puts the combined account – valued at approximately $600 million without digital spend, according to Nielsen figures – up for grabs, with Merck's incumbents Draftfcb and Initiative participating.

Schering-Plough incumbent Havas MPG is also in on the pitch, with final presentations planned for this March. Publicis Groupe's Zenith Media will also participate in the review, sources told Adweek. Participating agency sources verified the account review with MM&M, but couldn't offer any additional information or details, citing sensitivity on the issue. A spokesperson at Merck refused to confirm the review.

Merck alone is responsible for the bulk of the $600 million account, spending upwards of $520 million from January-November 2009. Draftfcb has previously handled planning and some buying, including digital and print. Initiative handles TV buying, according to the Adweek report.

Creative agencies that work on Merck and Schering brands, including Draftfcb, DDB Healthcare, Havas' Euro RSCG, Merkley + Partners, BBDO and TBWA\WorldHealth, are not included in the media-only review, per Adweek sources.

Interpublic Group's Initiative agency has fared well in large pharma media consolidations of late. Bayer consolidated its US media account with Initiative last November.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...